期刊
PATHOLOGY
卷 51, 期 4, 页码 345-348出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.pathol.2019.02.004
关键词
HER2 immunohistochemistry; in situ hybridisation; breast cancer
类别
资金
- Roche/Ventana
The latest update to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing in breast cancer guidelines was published in 2018. A multidisciplinary expert committee, convened under the auspices of the Royal College of Pathologists of Australasia (RCPA) Structured Pathology Reporting framework, evaluated the implications of these guidelines for clinical practice in Australia. Following feedback from professional bodies, including the RCPA and CanSAC, peer review was invited. The final document prepared by the authors, endorsed by the Expert Committee RCPA Structured Pathology Reporting of Breast Cancer and by CanSAC, is published herein.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据